Title |
Effects of Anakinra on Health-Related Quality of Life in a Patient with 1129G>A/928G>A Mutations in MVK Gene and Heterozygosity for the Mutation 2107C>A in CIAS1 Gene
|
---|---|
Published in |
Frontiers in Pediatrics, June 2017
|
DOI | 10.3389/fped.2017.00128 |
Pubmed ID | |
Authors |
Gianluigi Laccetta, Maria Tutera, Mario Miccoli, Rita Consolini |
Abstract |
Mevalonate kinase deficiency impairs several aspects of the patient's quality of life, thus early diagnosis and treatment are required to improve health-related quality of life (HRQOL). A 15-year-old patient with double heterozygosity for the mutations 1129G>A and 928G>A in MVK gene, heterozygosity for the mutation 2107C>A in CIAS1 gene and hyper-IgD syndrome phenotype, has been treated with anakinra with a reduction of 50% in the number of fever episodes per month, a reduction of 33% in the days of fever for each attack and normal blood tests in the intercritical phase. The RAND 36-Item Health Survey has been used for the assessment of HRQOL before and after the treatment with anakinra. The patient's quality of life showed an overall improvement of 27%; results showed a better improvement in role limitations due to physical health (50%). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 11 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 3 | 27% |
Student > Bachelor | 1 | 9% |
Student > Ph. D. Student | 1 | 9% |
Student > Master | 1 | 9% |
Professor > Associate Professor | 1 | 9% |
Other | 0 | 0% |
Unknown | 4 | 36% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 27% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
Social Sciences | 1 | 9% |
Immunology and Microbiology | 1 | 9% |
Unknown | 5 | 45% |